SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Taus upcoming oncology milestones are driving attention, particularly the completed IMPACT pancreatic-cancer trial enrollment and expected data, alongside further REGAIN glioblastoma updates. Traders are broadly optimistic about the expanding pipeline, while some emphasize that larger datasets are still needed to validate the early results.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results, particularly resilient parks performance and improving streaming profitability, have reinforced bullish sentiment and prompted analyst upgrades. Traders remain divided, with some seeing a turnaround while others point to the stocks long stretch of weak, range-bound performance.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is pulling back after a strong run as traders position ahead of earnings, with some wary of recent SaaS-sector weakness and the stocks valuation. Others remain bullish on growth and AI-driven commerce, while security concerns appear in some bearish posts but are not the dominant discussion.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC pipeline data. Bulls see the clinical and regulatory milestones as potential catalysts, while skeptics point to the steep decline, CEO share sales, limited transparency, possible dilution and uncertainty about filing timing; some also blame broader biotech weakness and thin trading.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias early third-quarter report and raised full-year revenue guidance are driving attention, with continued LUPKYNIS sales growth supporting the results. Traders are split between viewing the report as solid execution and frustration that the shares fell despite it, compounded by confusion over whether management held an earnings call.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys shares are drawing attention after a sharp post-earnings rally despite revenue and EPS misses; traders are focusing on premium subscriber growth, stronger gross margin, and an upbeat fourth-quarter profit outlook. The move has surprised some investors, who question why the stock rose on a mixed report, while bulls see the guidance and improving ad revenue as the more important signals.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback alongside other AI and semiconductor stocks, with traders citing stretched valuations, broad market pressure, and uncertainty ahead of earnings. The community is split between buyers treating the decline as an opportunity and bears warning that the stock remains overvalued and could fall further.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs planned equity offering and stock-funded Elisity cybersecurity acquisition have put dilution and capital allocation at the center of discussion, amid a steep selloff. Traders are divided between viewing the deal as an expansion into quantum security and questioning its cost, execution benefits, and impact on existing shareholders.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken in 2027 has sparked concerns about pricing and CorMedixs largest revenue driver, contributing to a sharp selloff. Traders are divided over the impact: some see a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS reimbursement estimates as a reason the reaction may be excessive.

NEAR Protocol (NEAR) is a cryptocurrency launched in 2020. NEAR Protocol has a current supply of 1,310,395,414. The last known price of NEAR Protocol is 4.30157975 USD and is up 6.10 over the last 24 hours. It is currently trading on 688 active market(s) with $1,245,620,491.67 traded over the last 24 hours. More information can be found at https://near.org/.

Near

Traders are watching a governance vote that could make NEAR less inflationary, with some viewing the tokenomics change as a potential catalyst. Sentiment is split: dip-buyers are accumulating, while cautious traders point to Bitcoin-linked weakness and liquidation risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corporate Developments Investors Can't Ignore

Across the markets companies are navigating pivotal moments that could shape their future, including NeOnc Technologies (NASDAQ:NTHI), Cemtrex (NASDAQ:CETX), Norwegian Cruise Line (NYSE:NCLH), Nuwellis (NASDAQ:NUWE), Teladoc Health (NYSE:TDOC), Bausch Health (NYSE:BHC), Insmed (NASDAQ:INSM), and Glaukos (NYSE:GKOS).

BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises

Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.

Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of +63.89% and +7.11%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027

Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027 Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027PR NewswireLAVAL, QC, Oct. 28, 2026 LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its...

Bausch Health Announces US$50 Million Share Repurchase Program

Bausch Health Announces US$50 Million Share Repurchase Program Bausch Health Announces US$50 Million Share Repurchase ProgramPR NewswireLAVAL, QC, Oct. 28, 2026 LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has...

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCEPR NewswireLAVAL, QC, Oct. 28, 2026 Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1basis over the prior year...

BHC Q3 Earnings Preview: Here's What You Should Know 

Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.

Bausch Health Pilot Study Shows Improved Cirrhosis Care Adherence

(RTTNews) - Bausch Health Companies Inc. (BHC, BHC.TO) and its gastroenterology unit Salix Pharmaceuticals, announced on Monday that a six-month pilot study of a standardized clinical pathway for Cirrhosis management improved adherence to guideline-based monitoring and treatment...

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical PathwayPR NewswireLAVAL, QC, Oct. 12...

$BHC Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $2.52 up 56.52% YoY
• Reported revenue of $4.19B up 56.17% YoY
• Bausch Health raised FY2026 guidance: consolidated revenue of $10.98B$11.18B and Adjusted EBITDA of $4.32B$4.42B; excluding Bausch + Lomb, revenue is $5.53B$5.63B, Adjusted EBITDA $3.23B$3.28B, and adjusted cash flows $1.6B$1.68B.

Stocktwits

Bausch Health Companies Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $2.52 up 56.52% YoY
• Reported revenue of $4.19B up 56.17% YoY
• Bausch Health raised FY2026 guidance: consolidated revenue of $10.98B$11.18B and Adjusted EBITDA of $4.32B$4.42B; excluding Bausch + Lomb, revenue is $5.53B$5.63B, Adjusted EBITDA $3.23B$3.28B, and adjusted cash flows $1.6B$1.68B.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $2.52 up 56.52% YoY
• Reported revenue of $4.19B up 56.17% YoY
• Bausch Health raised FY2026 guidance: consolidated revenue of $10.98B$11.18B and Adjusted EBITDA of $4.32B$4.42B; excluding Bausch + Lomb, revenue is $5.53B$5.63B, Adjusted EBITDA $3.23B$3.28B, and adjusted cash flows $1.6B$1.68B.

Bausch Healths Solta Medical organic revenue and Diversified nine-month organic revenue decreased, including Generics and Dentistry; the filing cites negotiated Xifaxan prices and says tariff impacts may be adverse.

Bausch Health reported Salix and Bausch + Lomb organic growth, fourteen consecutive quarters of revenue and Adjusted EBITDA growth excluding Bausch + Lomb, and cash generation supporting more than $500M of net debt reduction.

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’

Equity

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>CEO Thomas J. Appio said that the company is “disappointed in the results.”</li><li>The experimental therapy, however, was safe and well-tolerated, the company said.</li><li>Rifaximin is already approved in the U.S. and marketed as Xifaxan.</li></ul>Shares of Bausch Health Companies Inc. (BHC) fell 10% on Friday after the company said that its late-stage program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis failed to meet its primary goal.The clinical program <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bauschhealth.com/news-releases/2026/01-23-2026-124516159">evaluated</a> rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes. The program consisted of two global trials involving more than 1000 patients.Hepatic encephalopathy is a serious brain dysfunction caused by liver failure, where the liver can't remove toxins from the blood, allowing them to build up and affect the brain, causing confusion, personality changes, slurred speech, and lethargy, potentially leading to coma.<h2 class="st-heading-2">Executive Takeaway</h2>CEO Thomas J. Appio said that the company is “disappointed in the results.” The experimental therapy, however, was safe and well-tolerated, the company said.“We are currently reviewing the full dataset to determine potential new development opportunities," he said while adding that the company remains committed to bringing new treatments to patients across hepatology and other therapeutic areas.Rifaximin is already approved in the U.S. and marketed as Xifaxan which is slated to lose exclusivity in 2028. The recent trials were evaluating a new variant of the compound.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BHC stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while retail chatter rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed anticipation for the company’s quarterly report in February, saying the company “lost &nbsp;a &nbsp;Battle but not &nbsp;the &nbsp;war.”<stembedurl>https://www.stocktwits.com/Valmaro/message/642700352</stembedurl>Another user, however, opined that the trial failure is “a serious blow” to the company’s future prospects.<stembedurl>https://www.stocktwits.com/Contrarian_Dan/message/642693387</stembedurl><a href="https://stocktwits.com/symbol/BHC">BHC stock</a> has dropped 24% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-market-share-dives-in-ev-stronghold-california-in-2025-paving-way-for-asian-rivals-growth/cmUCgvWR4X8">Tesla’s Market Share Dives In EV Stronghold California In 2025, Paving Way For Asian Rival’s Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Bausch Health logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.

Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

SPDR Portfolio Developed World ex-US ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$8.20
Prev Close	$8.91
Open	$8.93
Dividend Yield	0.00%
50-Day Moving Average	$6.24
Beta	1.01
Avg. Volume	2.25M
PE Ratio	-3.58

52-Week High	$9.04
52-Week Low	$4.33
Market Capitalization	$3.07B
EPS (Annual)	$0.4187
Price to Book	-2.31
Revenue Per Employee	$505,714.29

Feed

News

Sentiment

Earnings

Fundamentals

Info

BHC Fundamentals